SUPRIYA

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about General Updates on ESG Ratings by CRISIL, receiving a rating of 'CRISIL ESG 65' in the 'Strong' category.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended September 30, 2026.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about General Updates regarding judicial proceedings. The company has filed a petition before the Hon'ble Supreme Court of India in connection with the matter and will keep the Stock Exchanges and shareholders informed of any material developments.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Supriya Lifescience Limited

Supriya Lifescience Limited held its 18th Annual General Meeting on September 24, 2026, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting commenced at 3.00 p.m. (IST) and concluded at 3.50 p.m. (IST). All resolutions were passed with requisite majority. The voting results along with the scrutinizer's report will be uploaded on the company's website and on the NSDL website.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about General Updates regarding a court order on the provisional release of a consignment of 200 kg of Ketamine Hydrochloride. The court has allowed the provisional release subject to a deposit of ₹72 lakh and has clarified that adjudication and criminal proceedings may continue in accordance with law.

Supriya Lifescience Limited

Supriya Lifescience Limited has clarified the absence of segment details in their quick results submitted on August 13, 2026, attributing it to a technical error. The company has a track record of timely and accurate disclosures and reaffirms their commitment to full compliance with the SEBI (LODR) Regulations, 2015.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about Schedule of meet for Analyst/Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015. The company will be interacting with Analyst/Institutional Investors on September 25, 2026, via a virtual group meeting. The investor presentation is available on the stock exchanges and the company's website.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about a schedule of meet with Analyst/Institutional Investors on September 17, 2026, and has uploaded the Investor Presentation on the Stock Exchanges and its website.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about General Updates, including the 18th Annual General Meeting (AGM) and the Annual Report for the Financial Year 2025-26.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about the ongoing judicial proceedings of its General Manager – Sales & Marketing, which are still sub judice and awaiting hearing and adjudication. The company will inform the Stock Exchanges of any material development, including any order passed by the Hon’ble Court, as and when received.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about the notice of its 18th Annual General Meeting, scheduled on September 24, 2026, published in newspapers.

Supriya Lifescience Limited

Supriya Lifescience Limited has been asked by the NSE to clarify its financial results for the quarter ended 30-Jun-2026 due to non-compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication regarding the 18th Annual General Meeting (AGM) of the Company to be held on September 24, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM).

Supriya Lifescience Limited

Supriya Lifescience Limited has announced the record date for the purpose of dividend as 04-Sep-2026. The company has recommended a final dividend of Re. 1.00/- per equity share of Rs. 2/- each for the FY 2025-26, subject to approval of members at the Annual General Meeting scheduled to be held on Thursday, September 24, 2026.

Supriya Lifescience Limited

Supriya Lifescience Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results. The company has passed the resolution for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel of the Company for a term of three (3) consecutive years from May 26, 2026, to May 25, 2029.

Supriya Lifescience Limited

Supriya Lifescience Limited has informed the Exchange about the transcript of the earnings call for the quarter ended June 30, 2026, where the company discussed its Q1 FY '27 results, including revenue growth, EBITDA margins, and new product launches.

Supriya Lifescience Limited

Supriya Lifescience Limited has made available the audio recording of its earnings call held on August 14, 2026, discussing its operational and financial performance for the quarter ended June 30, 2026, on its website.

Supriya Lifescience Limited

Supriya Lifescience Limited has published its unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results show a net profit of ₹1,184 for the quarter, with a basic earnings per share of ₹0.01.